1230 Bordeaux Dr
2 articles with NeuCyte, Inc.
The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions.
SUNNYVALE, Calif., May 8, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced the closing of a Series A financing round of $6.7 million, for a totaled funding of more than $8 million. NeuCyte's initial investors, Cowin Venture and Leaguer Ventures, led the round.